Susanne Ostrowitzki
Roche (Switzerland)(CH)
Publications by Year
Research Areas
Alzheimer's disease research and treatments, Cholinesterase and Neurodegenerative Diseases, Dementia and Cognitive Impairment Research, Parkinson's Disease Mechanisms and Treatments, Health Systems, Economic Evaluations, Quality of Life
Most-Cited Works
- → A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease(2017)561 cited
- → Mechanism of Amyloid Removal in Patients With Alzheimer Disease Treated With Gantenerumab(2011)429 cited
- → Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti–α-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease(2018)285 cited
- → Assessing tumor angiogenesis using macromolecular MR imaging contrast media(1997)255 cited
- → First‐in‐human assessment of PRX002, an anti–α‐synuclein monoclonal antibody, in healthy volunteers(2016)244 cited
- → Evaluating the Safety and Efficacy of Crenezumab vs Placebo in Adults With Early Alzheimer Disease(2022)198 cited
- → Dynamic contrast‐enhanced magnetic resonance imaging as a surrogate marker of tumor response to anti‐angiogenic therapy in a xenograft model of glioblastoma multiforme(2002)155 cited
- → Tau: From research to clinical development(2016)142 cited
- → Characterization of 3 Novel Tau Radiopharmaceuticals, 11 C-RO-963, 11 C-RO-643, and 18 F-RO-948, in Healthy Controls and in Alzheimer Subjects(2018)102 cited
- → A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA): Rationale, Design, and Baseline Data(2021)81 cited